A surveillance, epidemiology, and end results registry analysis of prostate cancer modality time trends by age

Am J Clin Oncol. 2010 Dec;33(6):619-23. doi: 10.1097/COC.0b013e3181c4c6e1.

Abstract

Objective: To use the Surveillance, Epidemiology, and End Results (SEER) registry to analyze age-specific time trends in the use of radiotherapy (RT) (external beam radiotherapy [EBRT], brachytherapy [brachy], and combination therapy [combo]) as first-line treatment for prostate cancer.

Methods: A total of 820,649 prostate cancer patients in the SEER public-use registry (1973-2004) with diagnosis year, treatment, and age information available were identified. Modality use time-trend curves were plotted for patients 45 to 85+ years of age, grouped in 5-year intervals. A nonparametric (Spearman) test was used to assess the correlation between diagnosis year and (a) percentage use of RT and (b) relative percentage use of EBRT, brachy, and combo therapy.

Results: Over the study period from 1973 to 2004, RT use increased in patients ≥65 years of age, but has remained stable in patients <65 years of age. All age groups experienced a similar relative rise in the use of brachy and combo therapy, with brachy use surpassing combo use in approximately year 2000.

Conclusions: Trends in treatment choice for early prostate cancer generally reflect treatment advances, but do not appear to be uniform among all age groups. The SEER database is a valuable asset for analyzing these trends and can be used to investigate age-specific treatment patterns.

Publication types

  • Comparative Study
  • Evaluation Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Age Factors
  • Aged
  • Brachytherapy / methods
  • Brachytherapy / trends*
  • Combined Modality Therapy
  • Disease-Free Survival
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local / mortality
  • Neoplasm Recurrence, Local / pathology
  • Neoplasm Staging
  • Prostate-Specific Antigen / blood*
  • Prostatectomy / methods
  • Prostatectomy / trends*
  • Prostatic Neoplasms / epidemiology*
  • Prostatic Neoplasms / pathology
  • Prostatic Neoplasms / radiotherapy*
  • Prostatic Neoplasms / surgery
  • Radiotherapy Dosage
  • Registries
  • Risk Assessment
  • SEER Program
  • Survival Analysis
  • Survival Rate
  • Time Factors
  • United States

Substances

  • Prostate-Specific Antigen